Identification of new human CYP2C19 alleies (CYP2C196 and CYP2C192B) in a caucasian poor metabolizer of mephenytoin

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 3, 1998, Pages 1490-1495

  Ibeanu, Gordon C ^a   Goldstein, Joyce A ^a   Meyer, Urs ^b   Benhamou, Simone ^c   Bouchardy, Christine ^d   Dayer, Pierre ^e   Ghanayem, Burhan I ^a   Blaisdell, Joyce ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c INSERM   (France)

^d GENEVA CANCER REGISTRY   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MEPHENYTOIN; TOLBUTAMIDE; ANTICONVULSIVE AGENT; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC DISORDER; GENOTYPE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; ALLELE; GENETICS; METABOLISM;

ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; MUTAGENESIS, SITE-DIRECTED;

EID: 0032159423     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Adedoyin A, Prakash C, O'Shea D, Blair IA and Wilkinson GR (1994) Stereo selective disposition of hexobarbital and its metabolites: Relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 4:27-38.
2. Andersson T, Regardh C-G, Lou Y-C, Zhang Y, Dahl ML and Bertilsson L (1992) Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2:25-31.
3. Balian JD, Sukhova N, Harris JW, Hewett J, Pickel L, Goldstein JA, Woosley RL find Flockhart DA (1995) The hydroxylation of omeprazole correlates with Smephenytoin metabolism: A population study. Clin Pharmacol Ther 57:662-669.
4. Barnes HJ, Arlotto MP and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli PNAS(USA) 88:5597-5601.
5. Baumann P, Jonzier-Perez M, Kerb L, Kupfer A, Tingueley D and Schöpf J (1956) Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychophirmacol 1:102-112.
6. Benhamou S, Bouchardy C and Dayer P (1997) Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics 7:157-159.
7. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J and Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 45:348-355.
8. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochim 72:248-254.
9. Br0sen K, deMorais SMF, Meyer UA and Goldstein JA (1995) A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5:312-317.
10. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR and Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
11. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA and Goldstein JA (1994b) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598.
12. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA and Goldstern JA (1994a) The major genetic defect responsible for the polymorphism of Smephenytoin in humans. J Biol Chem 269:15419-15422.
13. de Morais SMF, Goldstein JA, Xie H-G, Huang S-L, Lu Y-Q, Xia H, Xiao Z-S, Ile N and Zhou H-H (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharm Ther 58:404-412.
14. Deng WP and Nickoloff JA (1992) Site-directed mutagensis of virtually any plasmid by eliminating a unique site. Anal Biochem 200:81-88.
15. Ferguson RJ, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu <3, Wilkinson GR, Sarich TC, Wright JM, Dayer P and Goldstein JA (1998) A novel defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361.
16. Goldstein JA and Blaisdell J (1996) Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism in Methods in Enzymology:, Vol 272,Cytochrome P450, Part B, (ed. by E. F. Johnson and M. R.Waterman) pp. 210-217, Academic Press, San Diego, CA.
17. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI (1994) Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 33:1743-1752.
18. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM and Price Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American Black populations. Pharmacogenetics 7:59-64.
19. Gotoh 0 (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
20. Hahn GJ and Meeker WQ (1997) Statistical Intervals: A Guide for Practitioner's. John Wiley & Sons, Inc. pp. 104-105.
21. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA and Deisenhofer J ( 1995) Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 2:41-62.
22. Ibeanu GC, Ghanayem BI, Linko P, Leiping L, Pedersen LG and Goldstein JA (1996) Identification of residues 99, 220 and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. J Biol Chem 271:12496-12501.
23. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C!, Wilkinson GR, Dayer P, Daly AK and Goldstein JA (1998) An additional defective allele, CYP2C195, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8:129-135.
24. Kupfer A and Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Sur J Clin Pharmacol 26:753-759.
25. Kupfer A and Branch RA (1985) Stereo selective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 38:414-418.
26. Nielsen KK, Br0sen K, Hansen J and Gram LF (1994) Single-dose kinetics of clomipramine: relationship to the sparteine/debrisoquine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 55:518-527.
27. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
28. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ and Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450 of the 2C subfamily in Escherichia coli Arch Biochem Biophys 323:87-96.
29. Romkes M, Faletto MB, Blaisdell J, Raucy JL and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247-3255.
30. Sarich T, Kalhorn T, Magee S, Al-Sayegh F, Adams S, Slattery J, Goldstein J, Nelson S and Wright J (1997) The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharm Ther 62:21-28.
31. Sindrup SH, Br0sen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF and Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 13:11-17.
32. Skjelbo E, Br0sen K, Hallas J and Gram LF (1991) The mephenytoin oxidative polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49:18-23.
33. Tartof KD and Hobbs CA (1987) Improved media for growing plasmid and cosmid clones. Bethesda Res Lab Focus 9:19.
34. Ward SA, Walle T, Walle UK, Wilkinson GR and Branch RA (1989) Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther 45:72-79.
35. Ward SA, Helsby NA, Skejlbo E, Br0sen K, Gram LF and Breckenridge AM (1991)
36. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J din Pharmacol 31: 689-692.
37. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA and Wilkinson GR (1984) Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr B Biomed Appl 307:121-127.
38. Wedlund PJ, Sweetman BJ, Wilkinson GR and Branch RA (1987) Pharmacogenetic association between the formation of 4-hdroxymephenytion and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 15:277-279.
39. Wilkinson GR, Guengerich FP and Branch RA (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53-76.
40. Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 306:240-245.
41. Xiao ZS, Goldstein JA, Xie H-G, Blaisdell J, Wang W, Jiang C-H, Yan F-X, He N, Huang S-L, Xu Z-H and Zhou H-H (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exper Ther 281:604-609.
42. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J and Wedlund PJ (1992) Limitation to the use of urinary S/R mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 31:350-352.